Table 2. Measured NGF levels (mean level with standard deviation in parentheses) according to the subgroups.
| No-CIPN | CIPN | p-value† | |||
|---|---|---|---|---|---|
| Baseline NGF (pg/ml) | Follow-up NGF (pg/ml) | Baseline NGF (pg/ml) | Follow-up NGF (pg/ml) | ||
| Previous chemotherapy | |||||
| Yes (n = 18), mean(SD) | 12.2(6.61) | 8.03(5.73) | 9.4(5.55) | 5.67(4.45) | 0.964 |
| No (n = 27), mean(SD) | 8.26(3.43) | 10.34(7.98) | 10.60(5.83) | 7.25(4.19) | 0.048* |
| Disease | |||||
| Multiple myeloma (n = 32), mean(SD) | 9.68(4.75) | 9.98(8.23) | 10.31(5.92) | 5.54(3.84) | 0.063 |
| Lymphoma (n = 11), mean(SD) | 7.22(3.35) | 7.57(4.21) | 10.42(4.93) | 8.66(4.64) | 0.614 |
| Intervention during the study | |||||
| Bortezomib only (n = 22), mean(SD) | 11.2(5.12) | 7.84(7.22) | 11.1(5.49) | 7.15(3.34) | 0.810 |
| Thalidomide only (n = 7), median [IQR] | 4.69[3.99–5.39] | 10.1[9.67–10.5] | 5.85[3.81–6.97] | 0.80[0.69–1.56] | 0.095 |
| Vincristine only (n = 10), mean(SD) | 9.62(6.09) | 8.44(4.13) | 12.34(4.47) | 7.11(5.77) | 0.300 |
| Combination (n = 6), median [IQR] | 9.21[7.82–11.1] | 8.86[7.57–19.2] | 4.56[3.95–11.6] | 12.2[9.37–12.4] | 0.700 |
| Response | |||||
| CR (n = 10), mean(SD) | 12.4(6.41) | 7.17(5.79) | 12.6(7.06) | 5.90(5.12) | 0.686 |
| PR (n = 26), mean(SD) | 9.28(4.86) | 8.00(5.50) | 9.39(5.46) | 7.21(4.18) | 0.682 |
| Others (n = 9), median [IQR] | 8.46[5.87–10.70] | 12.0 [11.4–20.8] | 8.47[7.08–10.40] | 4.70[4.07–7.19] | 0.095 |
*p-value of <0.05 is considered statistically significant.
† p-value calculated by the comparison of △NGF (follow-up NGF level–baseline NGF level) between the CIPN group and the no-CIPN group.